Research & Clinical Trials
Advancing the Science of Psychedelic Healing
At Quantum Integral Healing Arts, our clinical practice is informed by active participation in groundbreaking psychedelic research. Through our research initiative, OpenMind Therapeutics, we contribute to the scientific evidence base supporting psychedelic-assisted therapy for mental health conditions.
Dr. Sidney Edsall, MD, DABMA
Chief Executive Officer, OpenMind Therapeutics
Site Physician, MAPS Phase III MDMA Clinical Trials
Dr. Edsall leads OpenMind Therapeutics, a clinical research organization conducting psychedelic medicine trials. She also serves as Site Physician for MAPS Phase III trials investigating MDMA-assisted psychotherapy for PTSD. Her involvement in cutting-edge research directly informs the ketamine-assisted therapy provided at Quantum Integral Healing Arts.
About OpenMind Therapeutics
OpenMind Therapeutics is our dedicated research initiative focused on advancing psychedelic medicine through clinical trials and scientific collaboration. Led by Dr. Sidney Edsall, OpenMind serves as a bridge between cutting-edge research and compassionate clinical care.
Visit OpenMind Therapeutics to learn more about our research.
Current Clinical Trials
Open Mind Therapeutics serves as a clinical trial site for FDA-approved research investigating psychedelic medicines for mental health conditions. Through participation in these groundbreaking studies, we're contributing to the scientific evidence that will shape the future of mental health treatment.
MAPS Phase III MDMA Clinical Trials
OpenMind Therapeutics serves as a clinical trial site for FDA-approved research investigating psychedelic medicines for mental health conditions. Dr. Edsall also participates in the MAPS Phase III Clinical Trials of MDMA-assisted psychotherapy for PTSD.
MAPS Phase III MDMA Clinical Trials
The MAPS trials investigate MDMA-assisted therapy for Post-Traumatic Stress Disorder, particularly for individuals who haven't responded to conventional treatments. This landmark research is part of the FDA approval process and represents decades of careful scientific work to bring psychedelic-assisted therapy into mainstream medicine.
What the research studies:
MDMA-assisted psychotherapy for treatment-resistant PTSD
Safety and effectiveness of combining psychedelic medicine with structured therapy
Long-term outcomes and sustained improvements in quality of life
How Research Informs Care at Quantum
Our active involvement in clinical trials directly enhances the ketamine therapy we provide at Quantum Integral Healing Arts:
Evidence-Based Protocols
Treatment approaches backed by scientific research, not guesswork. We apply therapeutic methods that have been rigorously tested and validated through clinical trials.
Cutting-Edge Training
Our providers receive specialized training in psychedelic-assisted therapy through research involvement. This means you're working with clinicians at the forefront of the field.
Access to Latest Findings
We stay current with the newest developments in psychedelic medicine, bringing insights from ongoing research directly into your treatment.
Expert Guidance Through Expanded States
Experience guiding patients through non-ordinary states of consciousness in research settings translates to more effective, compassionate support during your ketamine sessions.
Rigorous Safety & Ethical Standards
The screening processes, safety protocols, and ethical guidelines proven in clinical research inform how we prepare and support every patient.
Interested in Participating in Research?
If you're interested in learning about clinical trial opportunities, visit OpenMind Therapeutics or contact us to discuss whether you might be eligible for ongoing studies.
Not participating in a trial? Learn more about our ketamine-assisted therapy services at Quantum Integral Healing Arts.
Realize your true potential
Get in touch to learn more
